Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

Detailed price information for American Tower Corp (AMT-N) from The Globe and Mail including charting and trades.

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...